Evidence map›Paper›PMID 41994384›Full record

ArticlePakistan journal of medical sciences2026

Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function.

Peipei Wang, Xiaojing Zhang, Cheng Xiang, Guoying Li, Yajing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peipei WangPeipei Wang, Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang 050000, Heibei, China.
Xiaojing ZhangXiaojing Zhang, Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang 050000, Heibei, China.
Cheng XiangCheng Xiang, Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang 050000, Heibei, China.
Guoying LiGuoying Li, Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang 050000, Heibei, China.
Yajing ZhangYajing Zhang, Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang 050000, Heibei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the efficacy, safety, and immunomodulatory effects of thymalfasin in combination with different immune checkpoint inhibitor (ICI)-based regimens in patients with advanced driver gene-negative non-small cell lung cancer(NSCLC). Methodology: A retrospective analysis was conducted on 120 patients with advanced NSCLC treated at Shijiazhuang People's Hospital between January 2021 to December 2024. Patients were assigned to three groups: Group-A( Results: ORR and DCR did not differ significantly among groups( Conclusion: Thymalfasin combined with ICIs and chemotherapy, particularly platinum-based doublet regimens, may significantly prolong survival, enhance immune function, and improve quality of life in patients with advanced NSCLC, without increasing treatment-related toxicity.

Indexed as

Combination therapyEfficacyImmune checkpoint inhibitorImmune functionNon-small cell lung cancerSafetyThymalfasin

Identifiers

PMID41994384
PMCPMC13080045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.